DIAdvisor

The DIAdvisor is a large scale- integrating project (IP) aiming at development of a prediction based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes.

The DIAdvisor does not depend on specific sensor technologies and technologies like standard strip sensing, minimally invasive continuous glucose sensors and non-invasive methods.

For safety reason, the DIAdvisor system will be able to self-assess the confidence of its proposed decisions. For safety reasons as well as for the sake of therapy improvements the system connects and provides information and trends to the Health Care Provider.

Glucose prediction is difficult and requires advanced science. This can be achieved only by a well-balanced group of eminent experts including academics, clinicians, user representatives and leading companies. This includes physiological modelling, identification theory, control theory, medical device technology, risk management theory, sensor science and user understanding.

The expected impact of DIAdvisor will be improved diabetes control and quality of life in large populations of insulin treated patients, leading to fewer diabetic complications and lower Health Care costs. Moreover, the project will constitute a valuable opportunity for European companies to build up a special know-how leading products that profoundly and positively impacts the lives of millions with other indications than diabetes.

For further information, please visit:
http://www.diadvisor.eu/

Project co-ordinator:
Novo Nordisk A/S (Denmark)

Partners:

  • Novo Nordisk A/S (Denmark),
  • Johannes Kepler Universität Linz (Austria),
  • Lunds Universitet (Sweden),
  • Universita Degli Studi di Padova (Italy),
  • Centre Hospitalier Regional Universitaire de Montpellier (France),
  • Toumaz Technology Ltd (UK),
  • Sensor Technology and Devices Ltd (UK),
  • Ondalys SARL (France),
  • Romsoft SRL (Romania),
  • Institut Klinicke a Experimentalni Mediciny (Czech Republic),
  • RICAM, Österreichische Akademie der Wissenschaften (Austria),
  • Rambøll Danmark A/S (Denmark),
  • Federation Internationale du Diabete Region Europe (Belgium)

Timetable: from 03/2008 – to 02/2012

Total cost: € 9.284.061

EC funding: € 7.099.992

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...

Siemens Healthineers Introduces Symbia P…

Siemens Healthineers introduces Symbia Pro.specta™, a single-photon emission computed tomography/computed tomography (SPECT/CT) system with CE Mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging...